Imaging-based toxicity assay revealed dose-dependent synergistic efficacy of the combination in all tested HGSC organoid cultures (Figure 5B−F), independent of CCNE1, MYC or KRAS amplification, the site of origin of the tumour cells or previous exposure to the replication stress-inducing carboplatin-based neoadjuvant chemotherapy (NACT). Here, KRAS is linked to neoplasm.